# Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation

> **NCT00681343** · PHASE4 · COMPLETED · sponsor: **University of Miami** · enrollment: 38 (actual)

## Conditions studied

- Living-Donor Kidney Transplant

## Interventions

- **DRUG:** Thymoglobulin
- **DRUG:** Campath-1H
- **DRUG:** Daclizumab

## Key facts

- **NCT ID:** NCT00681343
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2006-10
- **Final completion:** 2007-10
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00681343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00681343, "Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00681343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*